In recent years, the glaucoma treatment marketplace has been inundated with new laser technologies, which have excited physicians and surgeons as they have completely reinvented and invigorated the glaucoma treatment paradigm. Today, glaucoma is on the rise and continues to be one of the leading causes of blindness and vision loss worldwide.
Nassima BENHATCHI and Yves LACHKAR, MDs
Glaucoma Institute, Saint Joseph Hospital, Paris (FRANCE)
Origins of surgical glaucoma treatment date
back to the mid 1800s when iridectomy was discovered as an effective surgical method for the treatment of acute glaucoma and sclerotomy was presented as a procedure for chronic glaucoma. Though advancements have continued to change the landscape of how to treat glaucoma, the approaches remain largely the same: relief of the pupillary block, external filtration, internal filtration, and ciliodestruction.
The objective of this study was to compare the effectiveness and the tolerance of SS-TSCPC with a duty cycle of 25% versus 31.3% with Supra 810 nm Subliminal Quantel Medical laser stimulation for advanced glaucoma.
Glaucoma is a leading cause of irreversible blindness affecting approximately 60 million people globally 40 years of age and older. Glaucoma is a disease that cannot be ignored, and the need for significant changes in how we diagnose, manage, and treat must be examined and applied whenever possible.
Since 1993, Quantel Medical develops, manufactures and markets innovative medical laser and ultrasound solutions.
World leader in ophthalmology, its lasers and ultrasounds are designed to diagnose and treat the four main causes of blindness: cataracts, glaucoma, diabetic retinopathy and macular degeneration; and also dry eye disease.
"*" indicates required fields
